InspireMD Reports Fourth Quarter and Full Year 2025 Financial Results

Core Insights - InspireMD, Inc. reported strong financial results for Q4 2025, with total revenue reaching $3.1 million, a 62% increase year-over-year, and a 25% sequential increase from Q3 2025 [4][11] - The company is experiencing robust growth in the U.S. market for its CGuard Prime carotid stent system and anticipates further market expansion with upcoming approvals for TCAR procedures [3][11] - InspireMD's net loss for Q4 2025 was $11.8 million, compared to a net loss of $9.2 million in Q4 2024, indicating increased operational expenses primarily due to the expansion of the U.S. commercial team [9][13] Financial Performance - Total revenue for the full year 2025 was $9.0 million, reflecting a 28% increase from $7.0 million in 2024 [10] - U.S. revenue for 2025 was $1.4 million, while international revenue was $7.6 million, an 8% increase from the previous year [10] - Gross profit for Q4 2025 was $1.2 million, representing 37.5% of revenue, up from 24.1% in Q4 2024, driven by higher margin sales in the U.S. [6][12] Operating Expenses - Total operating expenses for Q4 2025 were $13.3 million, an increase of $3.5 million compared to Q4 2024, mainly due to increased headcount and resources for the U.S. launch of CGuard Prime [7][13] - For the full year 2025, total operating expenses were $52.3 million, up from $35.0 million in 2024, reflecting ongoing investments in commercial operations [13] Future Outlook - The company expects revenue for 2026 to be between $13 million and $15 million, indicating anticipated growth of approximately 45% to 65% over 2025 [16] - InspireMD is focused on advancing its CGuard Prime product and expanding its market presence, with plans for further catalysts in 2026 to enhance adoption [3][11]